Oxford Biomedica plc (LON:OXB)
435.00
+8.50 (1.99%)
Sep 4, 2026, 4:35 PM GMT
Oxford Biomedica Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Oxford Biomedica stock has a consensus rating of "Buy" and an average price target of 712p. The average 1-year stock price forecast is 63.68% higher than the current stock price, while the lowest is 508p (+16.78%) and the highest is 900p (+106.90%).
Price Target: 712p (+63.68%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Oxford Biomedica stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates 900p | Buy | Reiterates | 900p | +106.90% | Sep 2, 2026 |
| Deutsche Bank | Deutsche Bank | Hold Reiterates 595p | Hold | Reiterates | 595p | +36.78% | Sep 2, 2026 |
| Jefferies | Jefferies | Buy Reiterates 827p | Buy | Reiterates | 827p | +90.11% | Jun 3, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates 950p | Buy | Reiterates | 950p | +118.39% | Mar 11, 2026 |
Financial Forecast
Revenue This Year
193.88M
from 168.74M
Increased by 14.90%
Revenue Next Year
242.32M
from 193.88M
Increased by 24.99%
EPS This Year
-0.21
from -0.27
EPS Next Year
-0.04
from -0.21
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is GBP.